Impact of SGLT2 inhibitors on kidney health and survival in patients with polycystic kidney disease and type 2 diabetes
Authors' conclusion
SGLT2i use was associated with reduced risks of dialysis, AKI, and mortality in patients with PKD and T2D. These findings highlight a potential renal and survival benefit in this high-risk group. However, results were derived using an emulation protocol and propensity score methods based on electronic health records.
Study context
- Population
- Patients with PKD and T2D, TriNetX U.S. network (2015–2022)
- Participants
- 31,070 patients3 emulated trials
- Exposure
- SGLT2i vs non-users, DPP-4i and GLP-1 RA
- Non-usersn = 2,640 pairsreference
- Outcome
- Dialysis, cardiovascular and mortality risks
Methodological detailspropensity score matching, electronic health records, TriNetX U.S. network
- Propensity score matching
- Electronic health records
- TriNetX U.S. network
Main finding
As reported in the abstract
Dialysis, AKI and mortality
HR
- SGLT2i vs Non-users · dialysis
- 0.657
- SGLT2i vs Non-users · acute kidney injury (AKI)
- 0.896
- SGLT2i vs Non-users · mortality
- 0.840
- SGLT2i vs DPP-4 inhibitors · dialysis
- 0.458
- SGLT2i vs DPP-4 inhibitors · AKI
- 0.835
- SGLT2i vs DPP-4 inhibitors · mortality
- 0.813
- SGLT2i vs GLP-1 RAs · dialysis
- 0.531
Observational data: associations, not effects.
Original publication
Impact of SGLT2 inhibitors on kidney health and survival in patients with polycystic kidney disease and type 2 diabetes. Diabetes Res Clin Pract. Published 30 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →